These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33094918)

  • 61. Yellow Wine Polyphenolic Compounds prevents Doxorubicin-induced cardiotoxicity through activation of the Nrf2 signalling pathway.
    Lin H; Zhang J; Ni T; Lin N; Meng L; Gao F; Luo H; Liu X; Chi J; Guo H
    J Cell Mol Med; 2019 Sep; 23(9):6034-6047. PubMed ID: 31225944
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
    Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
    Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardiac Expression of Esophageal Cancer-Related Gene-4 is Regulated by Sp1 and is a Potential Early Target of Doxorubicin-Induced Cardiotoxicity.
    Long D; Chen C; Li W; Peng W; Li D; Zhou R; Dang X
    Cardiovasc Toxicol; 2022 May; 22(5):404-418. PubMed ID: 35129819
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
    Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
    Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protective effect of Di'ao Xinxuekang capsule against doxorubicin-induced chronic cardiotoxicity.
    Li X; Liang J; Qin A; Wang T; Liu S; Li W; Yuan C; Qu L; Zou W
    J Ethnopharmacol; 2022 Apr; 287():114943. PubMed ID: 34954266
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways.
    El-Ela SRA; Zaghloul RA; Eissa LA
    Nutrition; 2022 Oct; 102():111732. PubMed ID: 35816809
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy.
    Pan H; Yang S; Cheng W; Cai Q; Shubhra QTH
    Trends Endocrinol Metab; 2023 Jul; 34(7):392-394. PubMed ID: 37246117
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
    Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
    Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
    Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
    Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.
    Wei S; Ma W; Yang Y; Sun T; Jiang C; Liu J; Zhang B; Li W
    Biochem Pharmacol; 2023 Aug; 214():115662. PubMed ID: 37331637
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
    Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
    Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
    Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
    van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
    Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
    Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3.
    Meng L; Lin H; Zhang J; Lin N; Sun Z; Gao F; Luo H; Ni T; Luo W; Chi J; Guo H
    J Mol Cell Cardiol; 2019 Nov; 136():15-26. PubMed ID: 31445005
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.